[Federal Register Volume 83, Number 212 (Thursday, November 1, 2018)]
[Rules and Regulations]
[Page 54881]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: C1-2018-23517]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF VETERANS AFFAIRS

38 CFR Part 4

RIN 2900-AO19


Schedule for Rating Disabilities: The Hematologic and Lymphatic 
Systems

Correction

    In rule 2018-23517 beginning on page 54250 in the issue of Monday, 
October 29, 2018, make the following correction:


Sec.  4.117   [Corrected]

0
In Sec.  4.117, On page 54255, in the table, entry 7703 should read as 
follows:

------------------------------------------------------------------------
 
------------------------------------------------------------------------
7703 Leukemia (except for chronic myelogenous leukemia):
    When there is active disease or during a treatment               100
     phase..............................................
    Otherwise rate residuals under the appropriate
     diagnostic code(s).................................
    Chronic lymphocytic leukemia or monoclonal B-cell                  0
     lymphocytosis (MBL), asymptomatic, Rai Stage 0.....
Note (1): A 100 percent evaluation shall continue beyond
 the cessation of any surgical therapy, radiation
 therapy, antineoplastic chemotherapy, or other
 therapeutic procedures. Six months after discontinuance
 of such treatment, the appropriate disability rating
 shall be determined by mandatory VA examination. Any
 change in evaluation based upon that or any subsequent
 examination shall be subject to the provisions of Sec.
  3.105(e) of this chapter. If there has been no
 recurrence, rate on residuals..........................
Note (2): Evaluate symptomatic chronic lymphocytic
 leukemia that is at Rai Stage I, II, III, or IV the
 same as any other leukemia evaluated under this
 diagnostic code........................................
Note (3): Evaluate residuals of leukemia or leukemia
 therapy under the appropriate diagnostic code(s).
 Myeloproliferative Disorders: (Diagnostic Codes 7704,
 7718, 7719)............................................
------------------------------------------------------------------------

[FR Doc. C1-2018-23517 Filed 10-31-18; 8:45 am]
 BILLING CODE 1301-00-D